Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of Medicinal Chemistry|April 22, 2024
Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's DiseaseHunter T Warren, Hannah N Saeger, Robert J Tombari, et al.
Scandinavian Journal of Work, Environment & Health|August 26, 2003
Prevention of farm injuries in DenmarkKurt Rasmussen, Ole Carstensen, Jens M Lauritsen, et al.
BMC Health Services Research|September 15, 2017
Costs associated with adverse events among acute patientsJakob Kjellberg, Rasmus Trap Wolf, Marie Kruse, et al.
Schizophrenia Bulletin|July 31, 2007
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptomsKurt Rasmussen, Mei-Ann Hsu, Stephen Noone, et al.
Danish Medical Journal|May 13, 2014
Work environment influences adverse events in an emergency departmentKurt Rasmussen, Anna Helene Meldgaard Pedersen, Louise Pape, et al.
ACS Chemical Neuroscience|October 13, 2025
Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and PsychedelicsRajiv Agrawal, Daniel Gillie, Alison Mungenast, et al.
International Journal of Hygiene and Environmental Health|November 8, 2024
Persistent organic pollutants among seafood processing workers in West GreenlandMaria Wielsøe, Manhai Long, Jakob Hjort Bønløkke, et al.
Frontiers in Psychiatry|May 26, 2012
Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockadeMatthew J Fell, Jason S Katner, Kurt Rasmussen, et al.
Behavioural Brain Research|December 14, 2018
Evaluation of 5-HT<sub>7</sub> receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient miceOlivia M Balcer, Matthew A Seager, Scott D Gleason, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 3, 2009
Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depressionDonald R Gehlert, Kurt Rasmussen, Janice Shaw, et al.
Pageof 6